All In MedTech

Device Trial Radar · NCT06700239

The STTAR-US Study: A Pivotal Study of Transcatheter Tricuspid Annular Repair in the US

Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingTitle says "pivotal". Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Dec 31, 2025

Primary completion

Jun 2027

Study completion Dec 2032

Sponsor

Lead sponsor
Micro Interventional DevicesNot on our public-company list
Sponsor type
Industry
First posted
Nov 21, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose of this clinical study is to demonstrate the safety and efficacy of MIA-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR grade ≥3) despite optimal medical therapy, who have been determined by the site's local heart team to be at intermediate or greater estimated risk for mortality and morbidity with tricuspid valve surgery.

Conditions

  • Tricuspid Regurgitation Functional
  • Tricuspid Regurgitation
  • Severe Tricuspid Valve Regurgitation

Interventions

  • MIA_T DeviceDevice

    MIA-T Device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy EndpointTime frame: 12 months
  2. Primary Safety EndpointTime frame: 30 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.